La vendita allo scoperto per Allurion Technologies dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Allurion Technologies. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Allurion Technologies (NYSE:ALUR) Azioni, Report sulle vendite allo scoperto

Allurion Technologies

Allurion Technologies Inc is a medical device company that focuses on creating a weight loss platform to treat overweight patients. Its platform, the Allurion Program, features the world's first and only swallowable, procedure-less intragastric balloon for weight loss and offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion VCS. Its proprietary intragastric balloon, the Allurion Balloon, is in the form of a swallowed capsule that is administered to patients under the guidance of a healthcare provider without surgery, endoscopy, or anesthesia.

Allurion Technologies Inc

Allurion Technologies, Inc. Warrants, each whole warrant exercisable to purchase 1.420455 shares of common stock at an exercise price of $8.10 per share of common stock

Altice USA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATUS#NYSE">ATUS</a>) reported quarterly losses of $(0.16) per share which missed the analyst consensus estimate of $(0.08) by 100 percent. This is a 220 percent decrease over losses of $(0.05) per share from the same period last year. The company reported quarterly sales of $2.15 billion which missed the analyst consensus estimate of $2.16 billion by 0.27 percent. This is a 4.40 percent decrease over sales of $2.25 billion the same period last year.

Earnings

Earnings Misses

News

ATUS

Altice USA Q1 EPS $(0.16) Misses $(0.08) Estimate, Sales $2.15B Miss $2.16B Estimate

Appian (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APPN#NASDAQ">APPN</a>) reported quarterly earnings of $0.13 per share which beat the analyst consensus estimate of $0.03 by 333.33 percent. This is a 154.17 percent increase over losses of $(0.24) per share from the same period last year. The company reported quarterly sales of $166.43 million which beat the analyst consensus estimate of $163.35 million by 1.88 percent. This is a 11.07 percent increase over sales of $149.84 million the same period last year.

Earnings Beats

APPN

Appian Q1 Adj. EPS $0.13 Beats $0.03 Estimate, Sales $166.43M Beat $163.35M Estimate

Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) will no longer sell the range extender battery pack for its Cybertruck. The range extender would have let the vehicle achieve a range of over 500 miles.
What Happened: Customers took to social media to share details of an email they received from Elon Musk's company titled "Update to your Cybertruck Range Extender Order." Tesla influencer Sawyer Merritt shared a screenshot in a post on the social media platform X on Wednesday.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">BREAKING: Tesla has cancelled the Cybertruck Range Extender. "We are no longer planning to sell the Range Extender for Cybertruck. As a result, we will be refunding your deposit in full" <a href="https://t.co/yb1xOqecX2">pic.twitter.com/yb1xOqecX2</a>
&mdash; Sawyer Merritt (@SawyerMerritt) <a href="https://twitter.com/SawyerMerritt/status/1920253628012470621?ref_src=twsrc%5Etfw">May 7, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
"We are no longer planning to sell the Range Extender for Cybertruck. As a result, we will be refunding your deposit in full." The email from Tesla said. The range extender was originally available for $16,000 as an extra battery pack that would be fitted on the Cybertruck's bed.
Why It Matters: The news comes in as Musk's EV giant is struggling to sell units of the Cybertruck. The company reportedly has over <a href="https://www.benzinga.com/markets/25/05/45216453/tesla-has-over-10000-units-of-unsold-cybertrucks-in-its-us-inventory-amid-poor-sales-report">10,000 units of unsold Cybertrucks</a> in its U.S. inventory.
In a bid to boost sales and appeal to a wider customer base, Tesla also revamped the truck's <a href="https://www.benzinga.com/news/25/04/44967503/cybertruck-gets-a-down-to-earth-redesign-as-tesla-shifts-to-traditional-pickup-marketing-amid-poor-s">marketing language and strategy </a>to position it as a utilitarian, rugged pickup truck.
Interestingly, the company recently offered <a href="https://www.benzinga.com/25/05/45245835/tesla-hands-out-free-1-year-supervised-fsd-trial-to-select-cybertruck-owners">select Cybertruck owners </a>a 1-year-long free trial of Supervised Full Self-Driving, provided that they subscribe to the service before the June 6, 2025, deadline.
Elsewhere, Tesla also launched a <a href="https://www.benzinga.com/markets/equities/25/04/44755221/tesla-unveils-new-cybertruck-long-range-trim-with-a-362-mile-range-and-reduced-features">cheaper, RWD version</a> of the truck, which offered longer range but missed out on some features like smaller wheels, reduced towing capacity and lower ground clearance. The model retails for $62,490 with the federal EV credit and offers 362 miles of range.
Price Action: TSLA is currently $280.80, gaining 1.66% in pre-market trading, according to<a href="https://pro.benzinga.com/dashboard"> Benzinga Pro data</a>.
Check out more of Benzinga&#8217;s Future Of Mobility coverage by<a href="https://www.benzinga.com/topic/mobility"> following this link</a>.&nbsp;
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/05/45244989/lucid-group-q1-2025-earnings-tesla-rival-announces-58-increase-in-deliveries-plans-to-introduce-a-mid-size-platform-in-2026">Tesla-Rival Lucid Announces 58% Increase In Deliveries, Plans To Introduce Mid-Size Platform In 2026</a></li>
</ul>
Photo courtesy: Jonathan Weiss / Shutterstock.com

Tech

TSLA

Elon Musk's Tesla Scraps Popular $16,000 Cybertruck Range Extender As Sales Dwindle In US

Company received approval from European Medicines Agency (EMA) for CLN-978; Phase 1 study in active, difficult-to-treat rheumatoid arthritis to initiate in Q2 2025
CLN-978 expands into Sjögren's disease; Phase 1 study in active, moderate to severe patients to initiate in the U.S. in Q2 2025
Zipalertinib REZILIENT1 results to be shared in oral presentation at 2025 ASCO Annual Meeting

CGEM

Cullinan Therapeutics Receives EMA Approval For CLN-978; Phase 1 Study In Active, Difficult-To-Treat Rheumatoid Arthritis To Initiate In Q2 2025

Guidance

XERS

Xeris Biopharma Holdings Raises FY2025 Sales Guidance from $255.00M-$275.00M to $260.00M-$275.00M vs $317.63M Est

Apyx Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APYX#NASDAQ">APYX</a>) affirms FY2025 sales outlook from $47.60 million-$49.00 million to $47.60 million-$49.00 million vs $48.03 million estimate.

APYX

Apyx Medical Affirms FY2025 Sales Guidance of $47.60M-$49.00M vs $48.03M Est

BlackSky Technology (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BKSY#NYSE">BKSY</a>) affirms FY2025 sales outlook from $125.00 million-$142.00 million to $125.00 million-$142.00 million vs $168.00 million estimate.

BlackSky Technology Inc. Class A Common Stock

BKSY

BlackSky Technology Affirms FY2025 Sales Guidance of $125.00M-$142.00M vs $168.00M Est

Dave (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DAVE#NASDAQ">DAVE</a>) reported quarterly earnings of $2.48 per share which beat the analyst consensus estimate of $0.79 by 213.92 percent. This is a 300 percent increase over earnings of $0.62 per share from the same period last year. The company reported quarterly sales of $108.00 million which beat the analyst consensus estimate of $100.80 million by 7.14 percent. This is a 46.74 percent increase over sales of $73.60 million the same period last year.

DAVE

Dave Q1 Adj. EPS $2.48 Beats $0.79 Estimate, Sales $108.00M Beat $100.80M Estimate

Axogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXGN#NASDAQ">AXGN</a>) reported quarterly losses of $(0.02) per share which missed the analyst consensus estimate of $0.02 by 200 percent. This is a 66.67 percent increase over losses of $(0.06) per share from the same period last year. The company reported quarterly sales of $48.56 million which beat the analyst consensus estimate of $48.32 million by 0.49 percent. This is a 17.36 percent increase over sales of $41.38 million the same period last year.

AXGN

Axogen Q1 Adj. EPS $(0.02) Misses $0.02 Estimate, Sales $48.56M Beat $48.32M Estimate

BlackSky Technology (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BKSY#NYSE">BKSY</a>) reported quarterly losses of $(0.42) per share which beat the analyst consensus estimate of $(0.45) by 6.67 percent. This is a 52.27 percent increase over losses of $(0.88) per share from the same period last year. The company reported quarterly sales of $29.54 million which missed the analyst consensus estimate of $29.90 million by 1.18 percent. This is a 21.90 percent increase over sales of $24.24 million the same period last year.

BlackSky Technology Q1 EPS $(0.42) Beats $(0.45) Estimate, Sales $29.54M Miss $29.90M Estimate

AUTL

Autolus Therapeutics Q1 EPS $(0.26), Inline

Needham analyst Quinn Bolton maintains IonQ (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IONQ#NYSE">IONQ</a>) with a Buy and lowers the price target from $54 to $50.

Price Target

Analyst Ratings

IONQ

Needham Maintains Buy on IonQ, Lowers Price Target to $50

Warner Bros. Discovery (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBD#NASDAQ">WBD</a>) reported quarterly losses of $(0.18) per share which missed the analyst consensus estimate of $(0.11) by 63.64 percent. This is a 55 percent increase over losses of $(0.40) per share from the same period last year. The company reported quarterly sales of $8.98 billion which missed the analyst consensus estimate of $9.60 billion by 6.45 percent. This is a 9.83 percent decrease over sales of $9.96 billion the same period last year.

Warner Bros. Discovery Q1 EPS $(0.18) Misses $(0.11) Estimate, Sales $8.98B Miss $9.60B Estimate

Akebia Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKBA#NASDAQ">AKBA</a>) reported quarterly earnings of $0.03 per share which beat the analyst consensus estimate of $(0.04) by 175 percent. This is a 133.33 percent increase over losses of $(0.09) per share from the same period last year. The company reported quarterly sales of $57.34 million which beat the analyst consensus estimate of $44.88 million by 27.75 percent. This is a 75.84 percent increase over sales of $32.61 million the same period last year.

AKBA

Akebia Therapeutics Q1 EPS $0.03 Beats $(0.04) Estimate, Sales $57.34M Beat $44.88M Estimate

ALGM

Allegro Microsystems Q4 Adj. EPS $0.06 Beats $0.05 Estimate, Sales $192.82M Beat $185.28M Estimate

BigCommerce Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIGC#NASDAQ">BIGC</a>) sees Q2 sales of $82.500 million-$83.500 million vs $84.22 million analyst estimate.

BIGC

BigCommerce Holdings Sees Q2 Sales $82.500M-$83.500M vs $84.22M Est

BigCommerce Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIGC#NASDAQ">BIGC</a>) widens FY2025 sales outlook from $342.10 million-$350.10 million to $335.10 million-$351.10 million vs $344.84 million estimate.

BigCommerce Holdings Widens FY2025 Sales Guidance from $342.10M-$350.10M to $335.10M-$351.10M vs $344.84M Est

Hydro One (TSX:<a class="ticker" href="https://www.benzinga.com/stock/H#TSX">H</a>) reported quarterly earnings of $0.60 per share which beat the analyst consensus estimate of $0.54 by 11.11 percent. This is a 22.45 percent increase over earnings of $0.49 per share from the same period last year. The company reported quarterly sales of $2.41 billion which beat the analyst consensus estimate of $2.28 billion by 5.61 percent. This is a 11.17 percent increase over sales of $2.17 billion the same period last year.

TSX:H

Hydro One Q1 EPS $0.60 Beats $0.54 Estimate, Sales $2.41B Beat $2.28B Estimate

Full Year 2025 Outlook
Santiago Giraldo, Chief Financial Officer of Tecnoglass, stated, "Based on our solid start to 2025, we are raising the low end of our previously provided full year revenue outlook, which we now expect to be in the range of $960 million to $1.02 billion, representing growth of approximately 11% at the midpoint of the range. We are narrowing our Adjusted EBITDA¹ outlook to a range of $305 million to $330 million, representing growth of approximately 15% at the midpoint of the range. Our outlook includes an estimated full year 2025 impact of approximately $25 million associated with higher input costs and tariffs on certain products, prior to mitigation efforts. The implied expansion in full year Adjusted EBITDA margin incorporates the benefit of our planned pricing actions and other strategic actions in place that we believe will more than offset the impact of tariffs for the remainder of the year. Backed by our solid industry positioning, we remain confident in our ability to deliver another year of profitable growth and strong cash flow generation."

TGLS

Tecnoglass Raises FY2025 Sales Guidance from $940.00M-$1.02B to $960.00M-$1.02B vs $986.95M Est

PZZA

Papa John's FY25 Outlook Reaffirmed: System-Wide Sales Up 2%-5%, Adjusted EBITDA $200M-$220M, North America Gross Restaurant Openings 85-115, International 180-200

Comments

Allurion Technologies

Vendite allo scoperto

Allurion Technologies (NYSE:ALUR) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO